Biofrontera submits study report of pharmacokinetics study to FDA
24 févr. 2021 08h30 HE
|
Biofrontera AG
Leverkusen, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces the...
Biofrontera AG: Ludwig Lutter appointed new Chief Financial Officer effective March 1, 2021
02 févr. 2021 10h35 HE
|
Biofrontera AG
Leverkusen, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical...
Biofrontera announces preliminary revenue figures for the full year 2020
08 janv. 2021 09h35 HE
|
Biofrontera AG
Leverkusen, Germany, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Biofrontera AG resolves mandatory conversion of subordinated mandatory convertible bonds
12 nov. 2020 04h27 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has issued a 1.00%...
Biofrontera reports third quarter and first nine months 2020 results
11 nov. 2020 07h00 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today published its...
Biofrontera AG: Receives reasons from the Federal Court of Justice for overturning ruling of the Cologne Higher Regional Court
14 oct. 2020 04h30 HE
|
Biofrontera AG
Leverkusen, Germany, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, had announced on...
Biofrontera AG reports completion of the clinical phase of the pharmacokinetics study
08 oct. 2020 11h04 HE
|
Biofrontera AG
Leverkusen, Germany, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, reports the...
Biofrontera AG: German Federal Supreme Court overturns ruling of the Cologne Higher Regional Court
22 sept. 2020 12h02 HE
|
Biofrontera AG
Leverkusen, Germany, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that in...
Admission to trading of Biofrontera’s 1.00% qualified subordinated mandatory convertible bond 2020/2021
20 août 2020 13h00 HE
|
Biofrontera AG
Leverkusen, Germany, Aug. 20, 2020 (GLOBE NEWSWIRE) -- On August 18, 2020, Biofrontera AG (shares of Biofrontera AG ISIN: DE 00 6046113) announced the successful placement of the 1.00% qualified...
Result of the subscription of the 1.00 % qualified subordinated mandatory convertible bond 2020/2021
13 août 2020 16h50 HE
|
Biofrontera AG
Leverkusen, Germany, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) announced on July 27, 2020 the issuance of the 1.00% qualified subordinated...